JP2024517641A5 - - Google Patents
Info
- Publication number
- JP2024517641A5 JP2024517641A5 JP2023564111A JP2023564111A JP2024517641A5 JP 2024517641 A5 JP2024517641 A5 JP 2024517641A5 JP 2023564111 A JP2023564111 A JP 2023564111A JP 2023564111 A JP2023564111 A JP 2023564111A JP 2024517641 A5 JP2024517641 A5 JP 2024517641A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- subject
- cancer
- human
- tgf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163177053P | 2021-04-20 | 2021-04-20 | |
| US63/177,053 | 2021-04-20 | ||
| PCT/US2022/025612 WO2022226101A1 (en) | 2021-04-20 | 2022-04-20 | Methods and compositions for genetic modification and therapeutic use of immune cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024517641A JP2024517641A (ja) | 2024-04-23 |
| JP2024517641A5 true JP2024517641A5 (https=) | 2025-05-16 |
Family
ID=83723226
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023564111A Pending JP2024517641A (ja) | 2021-04-20 | 2022-04-20 | 免疫細胞の遺伝子改変および治療的使用のための方法および組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240197782A1 (https=) |
| EP (1) | EP4326291A4 (https=) |
| JP (1) | JP2024517641A (https=) |
| CN (1) | CN117915928A (https=) |
| WO (1) | WO2022226101A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7698577B2 (ja) * | 2018-10-18 | 2025-06-25 | ボード オブ リージェンツ ザ ユニヴァーシティ オブ テキサス システム | 組織常在メモリー様ｔ細胞を生成するための方法及びその使用 |
| CN118871586A (zh) * | 2022-01-26 | 2024-10-29 | 奥泽生物疗法公司 | 用于改善关节功能的基因编辑 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0955378A1 (en) * | 1998-04-06 | 1999-11-10 | Bente Lomholt Langdahl | Method and kit for detecting a sequence variation in the human TGF-beta 1 gene |
| WO2000001410A1 (en) * | 1998-07-06 | 2000-01-13 | Beth Israel Deaconess Medical Center | Methods of inhibiting proliferative diseases by inhibiting tgf-beta mediated angiogenesis |
| KR101286053B1 (ko) * | 2011-06-13 | 2013-07-19 | 연세대학교 산학협력단 | ＴＧＦ－β１ 발현을 억제하는 ｓｈＲＮＡ |
| EP3610266A4 (en) * | 2017-04-12 | 2021-04-21 | Massachusetts Eye and Ear Infirmary | TUMOR SIGNATURE OF METASTASIS, COMPOSITIONS OF SUBSTANCES AND USES THEREOF |
| WO2019089884A2 (en) * | 2017-11-01 | 2019-05-09 | Editas Medicine, Inc. | Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy |
| JP2021525518A (ja) * | 2018-05-31 | 2021-09-27 | ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ | 細胞をゲノム編集及び活性化するための方法 |
| CN110904045A (zh) * | 2018-09-17 | 2020-03-24 | 中国科学院动物研究所 | 经修饰的t细胞、其制备方法及用途 |
| AU2020288829A1 (en) * | 2019-06-04 | 2021-12-02 | Nkarta, Inc. | Combinations of engineered natural killer cells and engineered T cells for immunotherapy |
| US20250127811A1 (en) * | 2021-01-28 | 2025-04-24 | Precision Biosciences, Inc. | Modulation of tgf beta signaling in genetically-modified eukaryotic cells |
-
2022
- 2022-04-20 EP EP22792434.7A patent/EP4326291A4/en active Pending
- 2022-04-20 WO PCT/US2022/025612 patent/WO2022226101A1/en not_active Ceased
- 2022-04-20 CN CN202280043506.3A patent/CN117915928A/zh active Pending
- 2022-04-20 JP JP2023564111A patent/JP2024517641A/ja active Pending
- 2022-04-20 US US18/555,846 patent/US20240197782A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7546925B2 (ja) | 核酸とｃａｒ修飾免疫細胞とを含む治療薬およびその使用 | |
| Casares et al. | CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-γ-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination | |
| Yoshizawa et al. | Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2 | |
| Gajewski et al. | Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization | |
| CN112533942A (zh) | 嵌合抗原受体细胞疗法中细胞因子释放综合征的抑制 | |
| Seeger | Immunology and immunotherapy of neuroblastoma | |
| JP2021525524A (ja) | がんを治療するためのキメラ抗原受容体ｔ細胞（ｃａｒ−ｔ） | |
| Tirapu et al. | Improving efficacy of interleukin‐12‐transfected dendritic cells injected into murine colon cancer with anti‐CD137 monoclonal antibodies and alloantigens | |
| Smits et al. | Immunotherapy of acute myeloid leukemia: current approaches | |
| JP7384896B2 (ja) | 主要組織適合遺伝子複合（ｍｈｃ）クラスｉｉ－発現癌細胞ワクチン、及び統合免疫応答を生じさせるための使用方法 | |
| Hallez et al. | Interleukin‐12‐secreting human papillomavirus type 16–transformed cells provide a potent cancer vaccine that generates E7‐directed immunity | |
| JP2024517641A5 (https=) | ||
| US20230279352A1 (en) | Methods for generating primary immune cells | |
| JP2024531234A5 (https=) | ||
| Qin et al. | Increased tumorigenicity, but unchanged immunogenicity, of transporter for antigen presentation 1-deficient tumors | |
| Ostrand‐Rosenberg et al. | Expression of MHC class II and B7–1 and B7–2 costimulatory molecules accompanies tumor rejection and reduces the metastatic potential of tumor cells | |
| WO2024113715A9 (zh) | 制备沉默nkg2a基因的nk细胞的方法及其用途 | |
| Xiang et al. | Regression of engineered tumor cells secreting cytokines is related to a shift in host cytokine profile from type 2 to type 1 | |
| Zaidi et al. | Novel Immunotherapeutic Approaches for the Treatment of Glioblastoma: SE Zaidi et al. | |
| Liu et al. | Enhancement of immunogenicity of tumor cells by cotransfection with genes encoding antisense insulin-like growth factor-1 and B7. 1 molecules | |
| US20240316106A1 (en) | Methods for generating primary immune cells | |
| Raes et al. | Active antitumor immunotherapy, with or without B7-mediated costimulation, increases tumor progression in an immunogenic murine T cell lymphoma model | |
| Hirshaut et al. | Harnessing T‐lymphocytes for human cancer immunotherapy | |
| Leong et al. | Generation of an antitumour immune response to a murine mesothelioma cell line by the transfection of allogeneic MHC genes | |
| Böhm et al. | Targeting an anti-viral CD8+ T cell response to a growing tumor facilitates its rejection |